Anti-BK Virus Immune Response and Kidney Transplantation (BKv)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01109186|
Recruitment Status : Unknown
Verified November 2012 by Nantes University Hospital.
Recruitment status was: Recruiting
First Posted : April 23, 2010
Last Update Posted : November 19, 2012
BK virus infections are very frequent during months following a kidney transplantation: a viral reactivation is observed for almost 50% of patients during first year. This reactivation leads to a viremia for 10 to 15% of patient during this same period. The most frequent complication is interstitial nephritis for 2 to 8% of patients (27 patients representing 2.7% during 6 years in Nantes).
An intensive et persisting viral replication, assessed by detection of high blood viral load, could evolved to a viral nephropathy which lead to a very pejorative functional issue for the graft.
Biological follow-up of these infections lay on the measures of viral load. Their positivity must alert the physician and lead him to modulate immunosuppressive treatment.
Actually, there is no real consensus about the modalities of pharmacological immunosuppression decrease (decrease dose or change of molecule).
Specific lymphocytic anti-BKv evaluated on several cohorts of patients permit to prove:
- weakness of immune cellular response for patient with high viremia
- increase of this response when viral load decrease These studies laid on detection of INFg synthesis by Elispot after stimulation with viral antigens and in vitro cellular expansion.
New prospective and longitudinal data comparing the immune cellular response (systematic and early) after graft between patients controlling or not BKv infection are necessary to improve the comprehension of illness natural history.
The investigators propose to enlarge the investigation of anti-BKv immune cellular response to other functions than IFNg synthesis in the aim of detecting the eventual role of polyfunctional lymphocytes for infection control. Furthermore, the investigators propose to identify better diagnostic and prognostic makers.
|Condition or disease||Intervention/treatment|
|Kidney Transplantation||Other: biological parameters|
|Study Type :||Observational|
|Estimated Enrollment :||120 participants|
|Official Title:||Role of Specific Immune Cellular Response in the Control of BK Virus Infection: Prospective Study, Monocentric and Longitudinal During the First Nine Months After a Kidney Transplantation|
|Study Start Date :||May 2010|
|Estimated Primary Completion Date :||May 2013|
|Estimated Study Completion Date :||May 2013|
Other: biological parameters
blood sample at M1, M2, M3; M4; M5, M6, M7, M8 and M9 after kidney transplantation
- Comparison of the level of response between patient with a "non-controlled infection" and patients for who the blood viral load is under 103 copBKv/ml. [ Time Frame: at 1month, 2months, 3months, 4, 5, 6, 7, 8 and 9 months after kidney transplantation ]Analyse the role of T-lymphocytes response in the control of BKv infection
- Analyse of the other causes that could influence the occurence of a viremia higher than 103 copBKv/ml [ Time Frame: at 1month, 2months, 3months, 4, 5, 6, 7, 8 and 9 months after kidney transplantation ]Other causes for abnormal viremia
- Measurement of histological consequences of a BKv non-controlled infection during the first year post-graft [ Time Frame: at 12 months after kidney transplantation ]Determine the frequence of occurence of nephropathy due to BKv for the population with a non-controlled infection
- Measurement of increase of immune response due to modifications of immunosuppressive treatment for patient with a non-controlled infection [ Time Frame: at 1, 3 et 6 months after modification of immunosuppressive treatment ]Comparision between the level of immune response and the time when the first viremia is higher than 103 copBKv/ml and 1, 3 et 6 months after modification of immunosuppressive treatment.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01109186
|Contact: Celin Bressollette, MDemail@example.com|
|Nantes' Univeristy hospital||Recruiting|
|Nantes, France, 44000|
|Contact: Celine Bressollette, MD 02.40.08.41.22 firstname.lastname@example.org|
|Principal Investigator: Celine Bressollette, MD|